bepridil bepridil bepridil (trade name vascor) is an diamine calcium channel blocker once used to treat angina pectoris. it is no longer sold in the united states. bepridilclinical datatrade namesvascorahfs/drugs.commonographmedlineplusa699051routes ofadministrationoralatc codec08ea02 (who) pharmacokinetic databioavailabilitywell absorbedprotein binding99%metabolismhepatic, cyp3a4-mediatedelimination half-life42 hoursexcretionrenalidentifiers iupac name n-benzyl-n-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline cas number64706-54-3 ypubchem cid2351iuphar/bps2337drugbankdb01244 ychemspider2261 yunii755bo701machebichebi:3061 ychemblchembl1008 ycomptox dashboard (epa)dtxsid3022663 chemical and physical dataformulac24h34n2omolar mass366.549 g·mol−13d model (jsmol)interactive image smiles o(cc(c)c)cc(n1cccc1)cn(c2ccccc2)cc3ccccc3 inchi inchi=1s/c24h34n2o/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24h,9-10,15-20h2,1-2h3 ykey:uieatewhfdryru-uhfffaoysa-n y (verify) it is nonselective. it has been discussed as a possible option in the treatment of atrial fibrillation. it has been implicated in causing ventricular arrhythmia (torsades de pointes). ebola research in june 2015 a research paper was published finding bepridil to result in a 100% survival rate for mice exposed to ebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy. sars-cov-2 research a research paper showed that bepridil inhibited cytopathogenic effects induced by sars-cov-2 in vero e6 cells and in a549 cells in an in vitro assay.